|
Sep 30
|
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
|
|
Aug 30
|
Why Neurocrine Biosciences Stock Was Tumbling This Week
|
|
Aug 29
|
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
|
|
Aug 29
|
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
|
Aug 29
|
Neurocrine reports positive data from Phase II schizophrenia treatment trial
|
|
Aug 28
|
Neurocrine Plummets 19% — Does It Still Have A Shot At This 'Significant Market Opportunity?'
|
|
Aug 28
|
Neurocrine Biosciences to Participate at Investor Conferences in September
|
|
Aug 28
|
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|
|
Aug 28
|
Neurocrine’s mixed schizophrenia data disappoint Wall Street
|
|
Aug 28
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
|
|
Aug 8
|
Statutory Profit Doesn't Reflect How Good Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are
|
|
Aug 7
|
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
|
|
Aug 6
|
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
|
|
Jul 10
|
Top Medical Stocks to Buy for Growth & Performance
|
|
Jun 14
|
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
|
|
Jun 12
|
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
|
|
May 29
|
Neurocrine Biosciences to Participate at Investor Conferences in June
|
|
May 28
|
Neurocrine Biosciences Announces CEO Succession Plan
|
|
May 28
|
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
|
|
May 14
|
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
|